

Psoralen Treated-Pathogen Reduced (PR) Large Volume Delayed Sampling (LVDS 36) Large Volume Delayed Sampling (LVDS 48) Effective June 1<sup>st</sup>,2021

## FOOD AND DRUG ADMINISTRATION(FDA) PLATELET BACTERIAL GUIDANCE

- FDA has established regulations to address the control of bacterial contamination of platelets. Under 21 CFR 606.145(a), blood establishments and transfusion services must assure that the risk of bacterial contamination of platelets is adequately controlled using FDA approved or cleared devices, or other adequate and appropriate methods found acceptable for this purpose by FDA. Implementation by 2021
- https://www.fda.gov/media/123448/download
- Recommendations to control the risk of bacterial contamination applies to:
  - Room temperature stored platelets intended for transfusion
  - Apheresis and Whole Blood derived platelets
  - Single Donor Platelets and Acrodose pools
  - Platelets in plasma and preservative



# **BLOOD SUPPLIERS TESTING STRATEGIES**

Single Step Strategies implemented to meet FDA guidance

- 1. Large Volume, Delayed Sampling (LVDS) ≥36 hours
- 2. Large Volume, Delayed Sampling (LVDS)  $\geq$ 48 hours
- 3. Pathogen Reduction
- Shelf Life- 5 to 7 days, hours in green indicate potential shelf life in TSL upon release from blood supplier





# LARGE VOLUME DELAYED SAMPLING (LVDS) LVDS 36 (NO SOONER THAN 36 HOURS)

- Single culture sampled no sooner than <u>36 hours</u> after collection
  - Single-step strategy
  - Inoculate both aerobic and anaerobic cultures
  - Minimum sample volume 16 mL
  - Sample each apheresis unit
    - Each split from a unit should be sampled
  - Minimum incubation 12 hours prior to release
  - **5 day** product expiration (48 hour hold time at blood supplier prior to release to TSL)
    - Can be extended beyond 5 days with verax PGD testing to day 6 and day 7 on non pas platelets



# LARGE VOLUME DELAYED SAMPLING (LVDS) LVDS 36 (NO SOONER THAN 36 HOURS)

### **Advantages:**

- Does not hold product as long as LVDS 48
- Secondary testing (Verax) can be applied to non PAS
- Lower Cost than Pathogen Reduction

### **Disadvantages:**

- Impact to available inventory
  - Holds product longer than Pathogen Reduction
  - Shelf life in TSL shorter than current state due to delayed release



# LARGE VOLUME DELAYED SAMPLING LVDS 48 (NO SOONER THAN 48 HOURS)

- Single culture sampled no sooner than <u>48 hours</u> after collection
  - Single-step strategy
  - Inoculate both aerobic and anaerobic cultures
  - Minimum sample volume 16 mL
  - Sample each apheresis platelet
    - Each split from a unit should be sampled
  - Minimum incubation 12 hours prior to release
  - 7 day product expiration (60 hour hold time at blood supplier prior to release to TSL)
  - Cannot extend beyond 7 days



# LARGE VOLUME DELAYED SAMPLING LVDS 48 (NO SOONER THAN 48 HOURS)

### **Advantages:**

- More likely to detect infectious agent with additional growth time
- Lower Cost than Pathogen Reduction
- 7-Day Product

### **Disadvantages:**

- Impact to available inventory
  - Holds product longer than Pathogen Reduction
- PAS platelets not eligible



### PATHOGEN REDUCTION (PR) PSORALEN TREATED/UVA LIGHT TREATMENT

- Targets DNA & RNA to prevent proliferation of pathogens
- Replacement for primary and secondary bacterial culture screening
- Approved alternative to Gamma Irradiation to prevent transfusion associated graft vs. host disease
- Apheresis platelets
- Currently 5 day expiration
- Do not centrifuge platelet in storage container, transfer contents to transfer pack for volume reduction. The PR platelet bags have a higher incidence of breakage that can occur during centrifugation
- Pathogen Reduced and PAS do not mean the same and are not interchangeable in their use



### PATHOGEN REDUCTION (PR) PSORALEN TREATED/UVA LIGHT TREATMENT

### Advantages:

- Product Availability Early Release, Optimal Shelf-Life
- Replaces Irradiation
- Replaces CMV testing

### **Disadvantages:**

- 5 Day expiration
- Higher Cost




### **AMERICAN RED CROSS** IMPLEMENTATION JUNE 1<sup>ST</sup>, 2021

American Red Cross will supply the following
PAS Psoralen Treated (PAS PR) platelets - majority of ARC collections will PAS PR
PAS non Psoralen Treated platelets
Apheresis in plasma (non PAS) platelets
All platelets have 5 day expiration



### PR PLATELETS IN PAS-C FROM ARC



#### Apheresis in Platelet Additive Solution (PAS-C)

E8340 Apheresis PLATELETS | ACD-A>PAS-C/XX/20-24C | ResLeu:<5E6 | Psoralen-treated

E8341 Apheresis PLATELETS | ACD-A>PAS-C/XX/20-24C | ResLeu:<5E<sup>6</sup> | 1st container | Psoralen-treated

E8342 Apheresis PLATELETS | ACD-A>PAS-C/XX/20-24C | ResLeu:<5E<sup>6</sup> | 2nd container | Psoralen-treated

E8343 Apheresis PLATELETS | ACD-A>PAS-C/XX/20-24C | ResLeu:<5E6 | 3rd container | Psoralen-treated

E8344 Apheresis PLATELETS | ACD-A>PAS-C/XX/20-24C | ResLeu:<5E6 | <3E11 plts | Psoralen-treated



# BLOODWORKS NORTHWEST

### IMPLEMENTATION AS EARLY AS JUNE 1<sup>st</sup>, 2021

- □ PAS platelets- (LVDS 36) *majority of BW supply to TSL will be PAS*
- Psoralen Treated (PR) platelets
- Apheresis in plasma (non PAS) platelets (LVDS 36 and LVDS 48)
- PAS, PR platelets will have 5 day expiration LVDS 36 have 5 day expiration eligible to extend to day 6 and 7 with verax for non pas
- LVDS 48 have 7 day expiration

BW expects to support TSL primarily with PAS 5 day and non PAS 7 day platelets. PR and non PAS 5 day platelets will also be provided in lesser quantities. BW will also be sending all platelet components either irradiated or pathogen reduced



## PAS PLATELETS LVDS 36H

#### 5-day PAS-F LVDS Apheresis Platelets - new ISBT Codes

Existing Codes	New Codes	PAS-F Irradiated
E7791	EA031	Apheresis PLATELETS ACD-A>PAS-F/XX/20-24C Irradiated ResLeu:<5E6 Bacterial Monitoring >=36h
E7792	EA032	Apheresis PLATELETS ACD-A>PAS-F/XX/20-24C Irradiated ResLeu:<5E6 1st container Bacterial Monitoring >=36h
E7793	EA033	Apheresis PLATELETS ACD-A>PAS-F/XX/20-24C Irradiated ResLeu:<5E6 2nd container Bacterial Monitoring >=36h
E7794	EA034	Apheresis PLATELETS ACD-A>PAS-F/XX/20-24C Irradiated ResLeu:<5E6 3rd container Bacterial Monitoring >=36h



## PR PLATFLETS

E8331Apheresis PLATELETS | ACD-A/XX/20-24C | ResLeu:<5E6 | Psoralen-treated</th>E8332Apheresis PLATELETS | ACD-A/XX/20-24C | ResLeu:<5E6 | 1st container | Psoralen-treated</td>E8333Apheresis PLATELETS | ACD-A/XX/20-24C | ResLeu:<5E6 | 2nd container | Psoralen-treated</td>E8334Apheresis PLATELETS | ACD-A/XX/20-24C | ResLeu:<5E6 | 3rd container | Psoralen-treated</td>



# NON PAS PLATELETS (LVDS36 AND LVDS48)

#### 5-day LVDS Apheresis Platelets - new ISBT codes

Ex	isting	New	Leukoreduced - Irradiated
С	odes	Codes	
E	3046	EA015	Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5E6 Bacterial Monitoring >=36h
E	3056	EA016	Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5E6 1st container Bacterial Monitoring >=36h
E	3057	EA017	Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5E6 2nd container Bacterial Monitoring >=36h
E	3058	EA018	Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5E6 3rd container Bacterial Monitoring >=36h

#### 7-day LVDS Apheresis Platelets - ISBT codes unchanged

Existing	Leukoreduced Irradiated	
Codes		
E5034	Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5E6 Bacterial monitoring 7D	
E5035	Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5E6 1st container Bacterial monitoring 7D	
E5036	Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5E6 2nd container Bacterial monitoring 7D	
E5037	Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5E6 3rd container Bacterial monitoring 7D	



### EXAMPLE OF LVDS 36 PLATELET



Bloodworks Seattle WA 98104 – 1256 FDA Registration Number 3071347



Properly Identify Intended recipient. See circular of information for Indications, contraindications, caulions, and methods of infusion. This product may transmit infectious agents. Rx only





EA031200 DIRECTED

APHERESIS PLATELETS PAS-F ADDED IRRADIATED LEUKOCYTES REDUCED BACTERIAL MONITORING > = 36 HOURS

258 mL containing approx \_\_\_\_\_ mL ACD – A Contains approx. 65% PAS/35% Plasma Store at 20 to 24 G




23 MAY 2021



### EXAMPLE OF LVDS 48 PLATELET





Ŷ

mL



APHERESIS PLATELETS IRRADIATED LEUKOCYTES REDUCED BACTERIAL MONITORING 7D 258 mL containing approx ACD – A

Store at 20 to 24 C 1st Container Expirat Date

**Rh POSITIVE** 





### EXAMPLE OF PATHOGEN REDUCE PLATELET



Bloodworke Seattle WA 98104 – 1256 FDA Registration Number 3071347



Property identify intended recipient. See circular of information for indications, contraindications, cautions, and methods of infusion. This product may fransmit infectious agents. Rx only



APHERESIS PLATELETS LEUKOCYTES REDUCED PSORALEN – TREATED

258 mL containing approx \_\_\_\_ mL ACD – A Store at 20 to 24 C



**Rh POSITIVE** 





# TRANSFUSION TAG COMPONENT DESCRIPTION

- P or PPH- PLATELET
- PAS- PAS PLATELET
- HLA- HLA PLATELET
- W-WASHED
- RV- VOLUME REDUCED
- I- IRRADIATED
- L-LEUKOREDUCED
- *PR* PATHOGEN REDUCED (PSORALEN TREATED on label)
- EXAMPLES
  - PPAS RV IL- PLATELET PAS VOLUME REDUCE IRRADIATED LEUKOREDUCED
  - PHLA 1 W IL- PLATELET HLA 1<sup>ST</sup> CONTAINER WASHED IRRADIATED LEUKOREDUCED
  - PPH2 PASLPR- PLATELET 2<sup>ND</sup> CONTAINER PAS LEUKOREDUCED PATHOGEN REDUCED



# SUMMARY-KEY POINTS

- Pathogen reduced is Psoralen Treated. Does not require irradiation
- Psoralen treated platelet bag cannot be centrifuged. Transfer to a transfer pack prior to centrifugation during volume reduction
- PAS platelets can be pathogen reduced or non pathogen reduced.
- Patient example: Patient blood type B pos and is a BMT: RV Plt A/O or PAS, irradiated or pathogen reduced. The following platelets are acceptable examples to provide to the patient:
  - Group B pas or non pas platelet irradiated
  - Group B pas or non pas platelet psoralen treated
  - Group A platelet PAS irradiated
  - Group A platelet PAS psoralen treated
  - Group A platelet non pas psoralen treated and volume reduced

